Roche Pharmaceutical Development and Sales Overview

Rituxan / Mabthera Global sales CHFbn CER growth -20% Regional sales 5.4 US 4.5 3.6 2.7 1.8 0.9 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 1,596m • US: Biosimilar erosion slowing • EU: Biosimilar erosion slowing . Japan: Biosimilar erosion slowing International: Biosimilar erosion slowing CER-Constant Exchange Rates CER growth -20% Europe -18% Japan -10% International -23% Roche 159

View entire presentation